Professor Aki Tsuchiya, PhD(Kyoto)
Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
Tel: (+44) (0)114 222 0710
Fax: (+44) (0)114 222 0749
Department of Economics
9 Mappin Street, Sheffield, S1 4DT, UK
Tel: (+44) (0)114 222 3422
Fax: (+44) (0)114 222 3458
I hold a joint appointment between the School of Health and Related Research (ScHARR) and the Department of Economics.
I came to the UK in 1998 as a Visiting Research Fellow at the Centre for Health Economics, University of York, funded as an Overseas Post-Doctoral Research Fellow of the Japan Society for the Promotion of Science. I came to Sheffield and joined ScHARR in 2000, where I worked as a Research Associate, a Research Fellow, and a Lecturer. Since 2005, I have held a joint appointment between ScHARR and the Department of Economics, as a Senior Lecturer, a Reader, and a Professor. Currently, I am a co-Director of the Centre for Well-being in Public Policy at the University, and a member of the EuroQol Group.
- measuring, valuing, and modelling health, and other aspects of well-being
- incorporating equity concerns into social welfare functions
- normative economics of health and beyond
- health economics for economists
- valuation of health states
- normative health economics
I teach health economics, which is about the application of economic concepts to matters of health, health care, and health care insurance. But, to what extent can we apply economics to matters of life and limb? Some think that whenever somebody’s life is at stake, it is unethical to think of costs, and thus “health” and “economics” sit very awkwardly with each other. However, if we ignore opportunity costs, then efficiency would be compromised and we would achieve less health overall. At the same time, most of us want a health care system that is not just efficient, but also equitable. Health economics enables the analysis of health care systems in the light of efficiency, equity, or both.
In health economics, there are numerous issues that involve value judgements, with no easy right answers. Should we use monetary valuation of health to analyse the efficiency of different drugs? Should health policy aim to maximise health or to maximise more general wellbeing? Should we forego any efficiency in order to improve equity in health outcomes? My approach to teaching is to encourage students to take an informed view on such issues, and then to defend these views (which may not agree with mine!).
I am interested in supervising PhD students in normative issues related to resource allocation and priority setting in health and wellbeing.
- SIPHER (System-science Informed Public Health and Economic Research for Non-communicable Disease prevention)
- Co-Director for Centre for Well-being in Public Policy
- Course Director for MSc Economics and Health Economics
- Co-Chair of the Athena SWAN Self-Assessment Group (ScHARR)
A full list of publications can be downloaded from the link in the box to the right of this page.
- Comparing aversions to outcome inequality and social risk in health and income : an empirical analysis using hypothetical scenarios with losses. Health Economics. View this article in WRRO
- How averse are the UK general-public to inequalities in health between socioeconomic groups? A systematic review. The European Journal of Health Economics. View this article in WRRO
- Manipulating the Five Dimensions of the EuroQol Instrument: The Effects on Self-Reporting Actual Health and Valuing Hypothetical Health States. Medical Decision Making. View this article in WRRO
- Striving for a societal perspective : a framework for economic evaluations when costs and effects fall on multiple sectors and decision-makers. Applied health economics and health policy. View this article in WRRO
- Equal access for equal need: Eliciting public preferences for access to health treatment by employment status. Social Science & Medicine, 222, 246-255. View this article in WRRO
- E‐learning and health inequality aversion: A questionnaire experiment. Health Economics, 27(11), 1754-1771. View this article in WRRO
- An exploration of the non‐iterative time trade‐off method to value health states. Health Economics, 27(8), 1247-1263. View this article in WRRO
- Using Discrete Choice Experiment with duration to model EQ-5D-5L health state preferences: Testing experimental design strategies. Medical Decision Making, 37(3), 285-297. View this article in WRRO
- Re-Thinking ‘The Different Perspectives That can be Used When Eliciting Preferences in Health’. Health Economics. View this article in WRRO
- Valuing health at the end of life: A stated preference discrete choice experiment. Social Science & Medicine, 124, 48-56. View this article in WRRO
- Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues.. Soc Sci Med, 114, 38-48. View this article in WRRO
- Preparatory study for the revaluation of the EQ-5D tariff: methodology report.. Health Technol Assess, 18(12), vii-191. View this article in WRRO
- Sick but satisfied: The impact of life and health satisfaction on choice between health scenarios. Journal of Health Economics, 32(4), 708-714.
- A Note on the Expected Biases in Conventional Iterative Health State Valuation Protocols. MEDICAL DECISION MAKING, 33(4), 544-546.
- Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI.. Value Health, 16(1), 104-113. View this article in WRRO
- A comparison of alternative variants of the lead and lag time TTO. Health Economics (United Kingdom), 22(5), 517-532.
- PUBLIC PREFERENCES FOR RESPONSIBILITY VERSUS PUBLIC PREFERENCES FOR REDUCING INEQUALITIES. HEALTH ECONOMICS, 21(12), 1416-1426.
- View this article in WRRO Is more health always better for society? Exploring public preferences that violate monotonicity.. Theory and Decision.
- Using a discrete choice experiment to estimate health state utility values.. J Health Econ, 31(1), 306-318.
- Valuing states from multiple measures on the same visual analogue sale: A feasibility study. Health Economics, 21(6), 715-729.
- A UNIFORM TIME TRADE OFF METHOD FOR STATES BETTER AND WORSE THAN DEAD: FEASIBILITY STUDY OF THE 'LEAD TIME' APPROACH. HEALTH ECON, 20(3), 348-361.
- The impact of adding an extra dimension to a preference-based measure.. Soc Sci Med, 73(2), 245-253.
- USING DCE AND RANKING DATA TO ESTIMATE CARDINAL VALUES FOR HEALTH STATES FOR DERIVING A PREFERENCE-BASED SINGLE INDEX FROM THE SEXUAL QUALITY OF LIFE QUESTIONNAIRE. HEALTH ECON, 18(11), 1261-1276.
- The social welfare function and individual responsibility: Some theoretical issues and empirical evidence (vol 28, pg 210, 2009). J HEALTH ECON, 28(3), 758-759.
- A comparison of patient and general population weightings of EQ-5D dimensions.. Health Econ, 18(3), 363-372.
- Equality of what in health? Distinguishing between outcome egalitarianism and gain egalitarianism.. Health Econ, 18(2), 147-159.
- The social welfare function and individual responsibility: Some theoretical issues and empirical evidence. J HEALTH ECON, 28(1), 210-220.
- Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.. Pharmacoeconomics, 27(12), 983-989.
- Public healthcare resource allocation and the Rule of Rescue. J MED ETHICS, 34(7). View this article in WRRO
- It ain't what you do, it's the way that you do it: Characteristics of procedural justice and their importance in social decision-making. J ECON BEHAV ORGAN, 64(1), 157-170.
- Do NHS clinicians and members of the public share the same views about reducing inequalities in health?. Soc Sci Med, 64(12), 2499-2503.
- Seeing for yourself: Feasibility study towards valuing visual impairment using simulation spectacles. HEALTH ECON, 16(5), 537-543.
- Assessing the economic challenges posed by orphan drugs: A comment on Drummond et al.. INT J TECHNOL ASSESS, 23(3), 397-401.
- Orphan drugs revisited.. QJM, 99(5), 341-345.
- Using rank data to estimate health state utility models.. J Health Econ, 25(3), 418-431. View this article in WRRO
- Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets.. J Health Econ, 25(2), 334-346.
- Severity of illness and priority setting: Worrisome criticism of inconvenient finding? - A reply to Erik Nord. J HEALTH ECON, 25(1), 173-174.
- Estimating the intangible victim costs of violent crime. BRIT J CRIMINOL, 45(6), 958-976.
- Orphan drugs and the NHS: should we value rarity?. BMJ, 331(7523), 1016-1019.
- Health priorities and public preferences: the relative importance of past health experience and future health prospects.. J Health Econ, 24(4), 703-714.
- Procedural justice in public health care resource allocation.. Appl Health Econ Health Policy, 4(2), 119-127.
- A "fair innings" between the sexes: are men being treated inequitably?. Soc Sci Med, 60(2), 277-286.
- A comparison of the EQ-5D and SF-6D across seven patient groups.. Health Econ, 13(9), 873-884. View this article in WRRO
- Exploring social welfare functions and violation of monotonicity: an example from inequalities in health. J HEALTH ECON, 23(2), 313-329.
- NICE's citizen's council: what do we ask them, and how?. LANCET, 362(9387), 918-919.
- Measuring people's preferences regarding ageism in health: some methodological issues and some fresh evidence.. Soc Sci Med, 57(4), 687-696.
- The person trade-off method and the transitivity principle: an example from preferences over age weighting.. Health Econ, 12(6), 505-510.
- Estimating an EQ-5D population value set: the case of Japan.. Health Econ, 11(4), 341-353. View this article in WRRO
- QALYs and ageism: philosophical theories and age weighting.. Health Econ, 9(1), 57-68.
- Age-related preferences and age weighting health benefits.. Soc Sci Med, 48(2), 267-276.